CN107643257A - A kind of composite reagent and its application and the kit containing the composite reagent - Google Patents
A kind of composite reagent and its application and the kit containing the composite reagent Download PDFInfo
- Publication number
- CN107643257A CN107643257A CN201710755835.1A CN201710755835A CN107643257A CN 107643257 A CN107643257 A CN 107643257A CN 201710755835 A CN201710755835 A CN 201710755835A CN 107643257 A CN107643257 A CN 107643257A
- Authority
- CN
- China
- Prior art keywords
- component
- reagent
- kit
- present
- composite reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to technical field of medical examination, more particularly to a kind of composite reagent and its application and the kit containing the composite reagent.The composite reagent includes component A and component B；The component A include soda acid buffer to, the propyl alcohol of 2 amino, 2 methyl 1, magnesium ion；The component B includes 4 Nitrophenyl phosphate sodium.Reagent composition provided by the invention, which can reach, improves reagent stability purpose, and the degree of accuracy is high, reproducible, the range of linearity is wide, strong antijamming capability.
Description
Technical field
The present invention relates to technical field of medical examination, more particularly to a kind of composite reagent and its application and contain the combination
The kit of reagent.
Background technology
Alkaline phosphatase (ALP) belongs to orthophosphoric ester monohydrolase, is one group of special phosphate.The enzyme is distributed widely in
Tissue and body fluid, higher with content in bone, liver, mammary gland, small intestine, kidney, normal human serum alkaline phosphatase is mainly by bone
Cell produces, and fraction comes from liver, drained through liver and gall.So when ALP produces excessive or excretion and is obstructed,
ALP in blood is set to change, ALP measure is mainly used for diagnosing liver and gall and disease of skeletal system, is reflection extrahepatic biliary passages stalk
The important indicator of occupying lesion and rickets in resistance, liver.
Alkaline phosphatase is higher to be divided into physiological rise and pathologic rise, and physiological rise is children's skeleton development
Phase, pregnant woman and union phase, the alkaline phosphatase in bone tissue is very active, and measurement result is higher；Property rise is common in disease
(1) skeletal diseases：Such as rickets, osteomalacia, bone malignant tumour, malignant metastatic tumor of bone；(2) disease in the liver and gallbladder such as liver outer bladder
Road obstruction, liver cancer, hepatic sclerosis, Cholestatic hepatitis etc.；(3) other diseases：Such as hyperparathyroidism.
At present, the detection method of alkaline phosphatase assay kit is mainly for base with 4- Nitrophenyl phosphates sodium (4-NPP)
The KINETIC METHOD of matter, this method are that method is recommended by international clinical chemistry association, and its principle is using 4- Nitrophenyl phosphates sodium the bottom of as
Thing, 2-amino-2-methyl-1-propanol (AMP) is the acceptor of phosphate acyl, under alkaline environment (pH 10 or so), ALP catalysis
4-NPP hydrolysis produces the paranitrophenol of yellow, and the generating rate and serum activity change of Alkaline phosphatase of p-nitrophenol are into just
Than increasing speed according to absorbance at 405nm so as to calculate ALP active units.
Decaying phenomenon after biochemical reagents corkage is to examine the FAQs in work, and the decay of reagent can cause to detect
As a result there is tendency change, be then considered as failure when decay degree exceedes scope or the time limit of reagent factory settings, therefore try
An important factor for agent corkage stability makes a variation in the daytime as influence reagent effect phase and testing result.For the hospital of middle and small scale
For, because its sample size is less, it is necessary to which the long period is just finished one bottle of reagent, therefore the corkage stability requirement to reagent
It is higher.However, existing current conventional alkaline phosphoric acid enzymatic determination reagent stability is nearly all undesirable, quality-control product typically can be steady
Fixed 13 days or so, sample is stablized 6 days or so, it is impossible to meets clinical detection demand.
The content of the invention
In view of this, the present invention provides a kind of composite reagent and its application and the kit containing the composite reagent.This hair
The reagent composition of bright offer, which reaches, improves reagent stability purpose, and the degree of accuracy is high, reproducible, the range of linearity is wide,
Strong antijamming capability.
In order to realize foregoing invention purpose, the present invention provides following technical scheme：
The invention provides a kind of composite reagent of detection of alkaline phosphatase, including component A and component B；
The component A include soda acid buffer to, 2-amino-2-methyl-1-propanol, magnesium ion；
The component B includes 4- Nitrophenyl phosphate sodium.
In some specific embodiments of the present invention, the buffering pair of soda acid described in the component A of the composite reagent
For sodium carbonate-bicarbonate buffering pair or potassium carbonate-bicarbonate buffering pair.
In some specific embodiments of the present invention, also include water in the component A of the composite reagent.
In some specific embodiments of the present invention, the component A of the composite reagent also includes zinc ion, N-
Mixture more than one or both of beta-hydroxy ethyl-3-acetic acid ethylenediamine, preservative.
In some specific embodiments of the present invention, the component A of composite reagent pH value for 9.0~
11.0。
In some specific embodiments of the present invention, the component B of the composite reagent also includes water.
In some specific embodiments of the present invention, the component B of the composite reagent also includes preservative.
In some specific embodiments of the present invention, the composite reagent in terms of mass parts, including following component：
The component A includes：
The component B includes：
0.5~10 part of 4-NPP
90~99.5 parts of water
The component A and component B mass ratio is 2~5:1.
In some specific embodiments of the present invention, the composite reagent in terms of mass parts, including following component：
The component A includes：
The component B includes：
0.5~10 part of 4-NPP
0.05~1.0 part of preservative
89~99.45 parts of water
The component A and component B mass ratio is 2~5:1.
In some specific embodiments of the present invention, the composite reagent in terms of mass parts, including following component：
The component A includes：
The component B includes：
0.5~10 part of 4-NPP
0.05~1.0 part of preservative
89~99.45 parts of water
The component A and component B mass ratio is 2~5:1.
In some specific embodiments of the present invention, the composite reagent in terms of mass parts, including following component：
The component A includes：
The component B includes：
0.5~5 part of 4-NPP
0.05~0.5 part of preservative
94.5~99.45 parts of water
The component A and component B mass ratio is 2~5:1.
In some specific embodiments of the present invention, the composite reagent in terms of mass parts, including following component：
The component A includes：
The component B includes：
0.5~5 part of 4-NPP
0.05~0.5 part of preservative
94.5~99.45 parts of water
The component A and component B mass ratio is 2~5:1.
In some specific embodiments of the present invention, the component A and component B mass ratio is 4:1.
In some specific embodiments of the present invention, the mass parts of the water in the component A are 70.7~98.69 parts；
The mass parts of water in the component B are 90~99.5 parts.
In some specific embodiments of the present invention, the composite reagent in terms of weight/mass percentage composition, it is including as follows
Component：
The component A includes：
The component B includes：
4-NPP 0.5~10%
Water 90~99.5%
The component A and component B mass ratio is 2~5:1.
In some specific embodiments of the present invention, the composite reagent in terms of weight/mass percentage composition, it is including as follows
Component：
The component A includes：
The component B includes：
4-NPP 0.5~10%
Preservative 0.05~1.0%
Water 89~99.45%
The component A and component B mass ratio is 2~5:1.
In some specific embodiments of the present invention, the composite reagent in terms of weight/mass percentage composition, it is including as follows
Component：
The component A includes：
The component B includes：
4-NPP 0.5~5%
Preservative 0.05~0.5%
Water 94.5~99.45%
The component A and component B mass ratio is 2~5:1.
In some specific embodiments of the present invention, the composite reagent in terms of weight/mass percentage composition, it is including as follows
Component：
The component A includes：
The component B includes：4-NPP 0.5~10%
Preservative 0.05~1.0%
Water 89~99.45%
The component A and component B mass ratio is 2~5:1.
In some specific embodiments of the present invention, the composite reagent in terms of weight/mass percentage composition, it is including as follows
Component：
The component B includes：4-NPP 0.5~5%
Preservative 0.05~0.5%
Water 94.5~99.45%
The component A and component B mass ratio is 2~5:1.
In some specific embodiments of the present invention, the acid-base reagent can be HCl or H2SO4。
In some specific embodiments of the present invention, the zinc ion is soluble zinc salt, is specifically as follows sulfuric acid
One or more in zinc, zinc chloride.
In some specific embodiments of the present invention, the magnesium ion is soluble magnesium salt, is specifically as follows chlorination
One or more in magnesium, magnesium sulfate, magnesium nitrate.
Present invention also offers application of the composite reagent in the detection instrument of alkaline phosphatase is prepared.
Present invention also offers a kind of kit of detection of alkaline phosphatase to include the composite reagent.
In some specific embodiments of the present invention, the mass ratio of sample to be tested and composite reagent provided by the invention
For 1：(40-60).
The invention provides a kind of composite reagent of detection of alkaline phosphatase, including component A and component B；The component A
Including soda acid buffering to, 2-amino-2-methyl-1-propanol, magnesium ion；The component B includes 4- Nitrophenyl phosphate sodium.
In the present invention, AMP refers to 2-amino-2-methyl-1-propanol, and HEDTA refers to the second of N- beta-hydroxies ethylethylenediamine three
Acid, 4-NPP refer to 4- Nitrophenyl phosphate sodium.Corkage stability test shows：Conventional reagents：Stability is opened, quality-control product can be steady
Fixed 13 days, sample is stablized 6 days；Reagent in kit of the present invention：Stability is opened, quality-control product can be stablized 23 days, and sample is stable
15 days.Other performance indications are consistent with now selling reagent, and accuracy is high, and precision is good, and the range of linearity is wide, strong antijamming capability, long
Phase stability is stablized 1 year.
Accuracy test shows that the measurement result and target value deviation of the kit that the present invention is supplied to meet《Alkaline phosphatase
Enzymatic determination kit (NPP substrate-AMP buffer methods) professional standard》It is required that illustrate that reagent accuracy of the present invention is good.
Replica test result shows that the coefficient of variation CV of seminal plasma fructose detection kit provided by the invention is ＜ 5%, is met
《Alkaline phosphatase assay kit (NPP substrate-AMP buffer methods) professional standard》It is required that and it is less than conventional reagents variation lines
Number, illustrates that kit of the present invention is reproducible.
Range of linearity testing result shows that linear high limit can accomplish 1000U/L, and relative deviation is less than 10%, met
《Alkaline phosphatase assay kit (NPP substrate-AMP buffer methods) professional standard》It is required that and linearly high limit will more than standard
750U/L is sought, illustrates that the kit range of linearity of the present invention is wide, it is applied widely.
Reagent interference test shows：Vc 1.0g/L, hemoglobin 5g/L, chyle TG 24mmol/L, the μ of bilirubin 800
Mol/L is noiseless to reagent measure, illustrates kit strong antijamming capability of the present invention.
Embodiment
A kind of kit the invention discloses composite reagent and its application and containing the composite reagent, art technology
Personnel can use for reference present disclosure, be suitably modified technological parameter realization.In particular, all similar replacements and
Change apparent to those skilled in the art, they are considered as being included in the present invention.The present invention method and
Using being described by preferred embodiment, related personnel can substantially not depart from present invention, spirit and scope
It is interior that method described herein and application are modified or suitably changed with combining, to realize and using the technology of the present invention.
A kind of composite reagent provided by the invention and its application and the kit containing the composite reagent in agents useful for same and
Raw material can be bought by market.With reference to embodiment, the present invention is expanded on further：
Embodiment 1：Alkaline phosphatase assay kit reagent is prepared
Wherein, component A pH is 9.0；By volume, component A：Component B=2:1.
Embodiment 2：Alkaline phosphatase assay kit reagent is prepared
Wherein, component A pH is 11.0；By volume, component A：Component B=3:1.
Embodiment 3：Alkaline phosphatase assay kit reagent is prepared
Wherein, component A pH is 9.5；By volume, component A：Component B=4:1.
Embodiment 4：Alkaline phosphatase assay kit reagent is prepared
Wherein, component A pH is 10.5；By volume, component A：Component B=5:1.
Embodiment 5：Alkaline phosphatase assay kit reagent is prepared
Wherein, component A pH is 10.0, by volume, component A：Component B=4:1.
Embodiment 6：Alkaline phosphatase assay kit reagent is prepared
Wherein, component A pH is 10.0；By volume, component A：Component B=4:1.
Embodiment 7：Alkaline phosphatase assay kit reagent is prepared
Wherein, component A pH is 10.0；By volume, component A：Component B=2:1.
Embodiment 8：Alkaline phosphatase assay kit reagent is prepared
Wherein, component A pH is 10.0；By volume, component A：Component B=5:1.
Comparative example 1：Alkaline phosphatase assay kit reagent is prepared
Wherein, component A pH is 10.0；By volume, component A：Component B=4:1.
Comparative example 2：Alkaline phosphatase assay kit reagent is prepared
Wherein, component A pH is 10.0；By volume, component A：Component B=4:1.
Embodiment 11：Alkaline phosphatase assay kit test method
1. instrument：With the automatic clinical chemistry analyzer or semi-automatic biochemical analyzer that wavelength is 405nm.
2. parameter setting and operation
Method：Performance rate method dominant wavelength：405nm commplementary wave lengths：505nm
Reaction temperature：37 DEG C of reaction time：10min
Sample measures concrete operation method is：Sample first with A37 DEG C of reagent component incubation 5 minutes, adds component B examinations
After 37 DEG C of agent incubates 1 minute, initial absorbance is determined, then Accurate Determining average minute clock absorbance change rate (Δ A/
min)。
Wherein, by volume, component A：Component B=2~5:1, (component A+ component B):Sample=40~60:1.
3. calculation formula
In formula：
ΔAU/ min-sample absorbance change rate；ΔAC/ min-calibration object absorbance change rate；CC--calibration object is dense
Degree.
Operating procedure：
1) set according to reagent parameter on instrument, reagent is put into instrument, select 2 points of calibrations, click starts
Button；
2) quality-control product and sample measures：Quality-control product or sample are put on instrument sample rack, in instrument working interface editor
Test sample project and test number, click on start button.
Embodiment 12：Alkaline phosphatase assay kit opens stability experiment
1. taking biochemistry quality control product level 1 and 2, add purified water to be dispensed after redissolving according to regulation volume and be stored in -20 DEG C, use
In reagent stability observing.
2. taking 10 clinical samples, small size packing is stored in -20 DEG C, for reagent stability observing.
After 3. the alkaline phosphatase assay kit that Example 1 to 5 provides is calibrated according to the method described above, measure
Quality-control product and 10 clinical samples, reagent opening are put on instrument, determine quality-control product and clinical sample, are control with deviation 10%
Line processed, observe reagent stability.
The corkage data for the kit measurement quality-control product that embodiment 1 to 8 provides are shown in Table 1~table 8.
The corkage data for the kit measurement quality-control product that the embodiment 1 of table 1 provides
The corkage data for the kit measurement quality-control product that the embodiment 2 of table 2 provides
The corkage data for the kit measurement quality-control product that the embodiment 3 of table 3 provides
The corkage data for the kit measurement quality-control product that the embodiment 4 of table 4 provides
The corkage data for the kit measurement quality-control product that the embodiment 5 of table 5 provides
The corkage data for the kit measurement quality-control product that the embodiment 6 of table 6 provides
The corkage data for the kit measurement quality-control product that the embodiment 7 of table 7 provides
The corkage data for the kit measurement quality-control product that the embodiment 8 of table 8 provides
The corkage data for the kit measurement clinical sample that embodiment 1 to 8 provides are shown in Table 9~table 16.
The corkage data for the kit measurement clinical sample that the embodiment 1 of table 9 provides
The corkage data for the kit measurement clinical sample that the embodiment 2 of table 10 provides
The corkage data for the kit measurement clinical sample that the embodiment 3 of table 11 provides
The corkage data for the kit measurement clinical sample that the embodiment 4 of table 12 provides
The corkage data for the kit measurement clinical sample that the embodiment 5 of table 13 provides
The corkage data for the kit measurement clinical sample that the embodiment 6 of table 14 provides
The corkage data for the kit measurement clinical sample that the embodiment 7 of table 15 provides
The corkage data for the kit measurement clinical sample that the embodiment 8 of table 16 provides
Alkaline phosphatase assay kit carries out above-mentioned corkage stability test, the alkali as a result prepared with embodiment 1~8
Acid phosphatase measure kit results are close, and no significant difference (P ＞ 0.05), quality-control product can be stablized 23 days, and clinical sample is stable
15 days.
The kit of comparative example 1 detection quality-control product the results are shown in Table 17：
The kit of 17 comparative example of table 1 detects quality-control product result
The kit of comparative example 1 detection clinical sample the results are shown in Table 18.
The kit of 18 comparative example of table 1 detects clinical sample result
The kit detection quality-control product that comparative example 2 provides the results are shown in Table 19：
The kit detection quality-control product result that the comparative example 2 of table 19 provides
The kit detection clinical sample that comparative example 2 provides the results are shown in Table 20：
The kit detection clinical sample result that the comparative example 2 of table 20 provides
Conventional reagents box detection quality-control product the results are shown in Table 21：
Conventional reagents box detection clinical sample the results are shown in Table 22：
Conclusion：Alkaline phosphatase assay kit corkage stability of the present invention is superior to conventional reagents, and quality-control product can be stablized
23 days, clinical sample was stablized 15 days；Conventional reagents corkage stability Quality Control is stablized 13 days, and sample can only be stablized 6 days.
Embodiment 13：Alkaline phosphatase assay kit other performance evaluations of embodiment 5
1. the degree of accuracy：Alkaline phosphatase quality-control product is determined, replication 3 times, calculates measured value and target value deviation.It is shown in Table
23：
The accuracy estimating result of table 23
Conclusion：Found out by result above, measurement result and target value deviation ＜ 10%, met《Alkaline phosphatase assay reagent
Box (NPP substrate-AMP buffer methods) professional standard》It is required that illustrate that reagent accuracy of the present invention is good.
2. repeated experiment：Using routine clinical sample as testing sample, made with conventional reagents and the embodiment of the present invention 5
The seminal plasma fructose detection kit replication obtained 10 times, calculate coefficient of variation CV%.It is shown in Table 24：
The reproducibility result of table 24
Conclusion：From result above, the coefficient of variation CV for the seminal plasma fructose detection kit that the embodiment of the present invention 5 provides is
0.74%, 0.29%, ＜ 5%, meets《Alkaline phosphatase assay kit (NPP substrate-AMP buffer methods) professional standard》
It is required that and be less than the conventional reagents coefficient of variation, illustrate that kit of the present invention is reproducible.
3. the range of linearity detects：Alkaline phosphatase concentration is taken close to 1000U/L serum high level, be diluted to 5 it is different dense
Spend (xi), the reagent in the kit provided with the embodiment of the present invention 5 calculates flat according to each concentration mensuration of detection method 3 times
Average (yi).Using xi as independent variable, equation of linear regression is obtained by dependent variable of yi, calculates linear regression correlation coefficient r；Will
Xi substitutes into equation of linear regression, calculates yi estimated value and the deviation of yi and estimated value.It is shown in Table 25：
The range of linearity testing result of table 25
Conclusion：Linearly dependent coefficient r is 1.00, more than 0.99；In the range of 25-100U/L, absolute deviation 1.07U/L,
Less than 10U/L, in the range of 100-1000U/L, relative deviation is less than 10%, meets《Alkaline phosphatase assay kit (NPP bottoms
Thing-AMP buffer methods) professional standard》It is required that and linearly high limit more than standard requirement 750U/L, illustrates reagent box line of the present invention
Property scope is wide, applied widely.
4. reagent interference experiment：Vc interference concentration (g/L) is prepared with basal serum：0.2、0.4、0.6、0.8、 1.0；Blood
Lactoferrin (g/L)：1、2、3、4、5；Chyle (TG mmol/L)：1000、2000、 4000、5000、6000；Bilirubin (μm ol/
L)：100th, a series of 200,400,600,800 analysis samples, the kit provided with the embodiment of the present invention 5 are determined and are free of simultaneously
Basal serum and above series of the analysis sample of interfering material, the relative deviation of analysis sample and basal serum is calculated, with
10% is interference control line, investigates kit antijamming capability.It is shown in Table 26：
The reagent interference test result of table 26
Conclusion：Visible Vc 1.0g/L of result above, hemoglobin 5g/L, chyle TG 24mmol/L, the μ of bilirubin 800
Mol/L is noiseless to reagent measure, illustrates kit strong antijamming capability of the present invention.
Reagent in the kit provided with the method for embodiment 14 embodiment 1~4, embodiment 6~8 carries out above-mentioned
Performance evaluation, as a result：
1. the degree of accuracy, embodiment 1~4, the reagent RE/% of embodiment 6~8 are equal<5%, experimental result is good；
2. repeatability, embodiment 1~4, the reagent of embodiment 6~8 are respectively 0.81%, 0.72%, 0.83%, 0.78%,
0.79%, 0.8%, 0.81%,<5%, experimental result is good；
3. linear, linear high limit of embodiment 1~4, the reagent of embodiment 6~8 can accomplish 1000U/L, and experimental result is good
It is good；
4. interference, embodiment 1~4, the reagent of embodiment 6~8, Vc 1.0g/L, hemoglobin 5g/L, chyle TG
800 μm of 24mmol/L, bilirubin ol/L are noiseless to reagent measure, illustrate reagent strong antijamming capability.
Above-described embodiment 1~4, the result of the test of embodiment 6~8 are corresponding to seminal plasma fructose detection kit prepared by embodiment 5
Result of the test is close, no significant difference (P ＞ 0.05).Show：The degree of accuracy of kit provided by the invention, repeatability, line
Property, strong antijamming capability.
Described above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications
It should be regarded as protection scope of the present invention.
Claims (4)
- A kind of 1. composite reagent of detection of alkaline phosphatase, it is characterised in that in terms of mass parts, including following component：The component A includes：The component B includes：0.5~10 part of 4- Nitrophenyl phosphates sodium0.05~1.0 part of preservative89~99.45 parts of waterThe component A and component B mass ratio is 2~5:1.
- 2. the composite reagent of the detection of alkaline phosphatase according to belonging to claim 1, it is characterised in that in terms of mass parts, including Following component：The component A includes：The component B includes：0.5~5 part of 4- Nitrophenyl phosphates sodium0.05~0.5 part of preservative94.5~99.45 parts of waterThe component A and component B mass ratio is 2~5:1.
- 3. application of the composite reagent according to claim 1 or 2 in the detection instrument of alkaline phosphatase is prepared.
- 4. a kind of kit of detection of alkaline phosphatase, it is characterised in that including composite reagent as claimed in claim 1 or 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710755835.1A CN107643257B (en) | 2015-11-02 | 2015-11-02 | Combined reagent, application thereof and kit containing combined reagent |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510728075.6A CN105259173B (en) | 2015-11-02 | 2015-11-02 | A kind of composite reagent and its application and the kit containing the composite reagent |
| CN201710755835.1A CN107643257B (en) | 2015-11-02 | 2015-11-02 | Combined reagent, application thereof and kit containing combined reagent |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510728075.6A Division CN105259173B (en) | 2015-11-02 | 2015-11-02 | A kind of composite reagent and its application and the kit containing the composite reagent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107643257A true CN107643257A (en) | 2018-01-30 |
| CN107643257B CN107643257B (en) | 2021-01-01 |
Family
ID=55098943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510728075.6A Active CN105259173B (en) | 2015-11-02 | 2015-11-02 | A kind of composite reagent and its application and the kit containing the composite reagent |
| CN201710755835.1A Active CN107643257B (en) | 2015-11-02 | 2015-11-02 | Combined reagent, application thereof and kit containing combined reagent |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510728075.6A Active CN105259173B (en) | 2015-11-02 | 2015-11-02 | A kind of composite reagent and its application and the kit containing the composite reagent |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105259173B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4176075A1 (en) * | 2020-07-01 | 2023-05-10 | Vision Diagnostics, Inc. | Assays and method for measuring alkaline phosphatase activity in urine as an index of tissue zinc deficiency |
| CN111876465B (en) * | 2020-07-30 | 2022-11-25 | 武汉生之源生物科技股份有限公司 | High-stability ALP (alpha-amyloid peptide) determination kit and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4555484A (en) * | 1983-07-25 | 1985-11-26 | Eastman Kodak Company | Analytical element and method for alkaline phosphatase assay |
| CN102297962A (en) * | 2011-05-23 | 2011-12-28 | 董理 | Kit for detecting alkaline phosphatase |
| CN103276051A (en) * | 2013-05-24 | 2013-09-04 | 宁波美康生物科技股份有限公司 | Alkaline phosphatase detection reagent |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19846301A1 (en) * | 1998-10-08 | 2000-04-13 | Roche Diagnostics Gmbh | Optical assay for determining alkaline phosphatase in samples uses specified primary and secondary measurement wavelengths |
| EP1386971B1 (en) * | 2001-04-17 | 2012-05-30 | Sysmex Corporation | Method of assaying biological component |
| CN103675282B (en) * | 2013-11-27 | 2016-01-20 | 新昌县美迪生物科技有限公司 | NBAP immue quantitative detection reagent box and uses thereof |
| CN104263831A (en) * | 2014-09-28 | 2015-01-07 | 南京诺唯赞生物科技有限公司 | Method for simply, conveniently and quickly determining activity of alkaline phosphatase |
| CN104990912B (en) * | 2015-06-26 | 2018-04-20 | 江苏浩欧博生物医药股份有限公司 | A kind of enzyme-catalyzed chemical luminescence substrate of alkaline phosphatase |
-
2015
- 2015-11-02 CN CN201510728075.6A patent/CN105259173B/en active Active
- 2015-11-02 CN CN201710755835.1A patent/CN107643257B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4555484A (en) * | 1983-07-25 | 1985-11-26 | Eastman Kodak Company | Analytical element and method for alkaline phosphatase assay |
| CN102297962A (en) * | 2011-05-23 | 2011-12-28 | 董理 | Kit for detecting alkaline phosphatase |
| CN103276051A (en) * | 2013-05-24 | 2013-09-04 | 宁波美康生物科技股份有限公司 | Alkaline phosphatase detection reagent |
Non-Patent Citations (1)
| Title |
|---|
| 张抗译: "测定人血清碱性磷酸酶活性的一个参考方法", 《国外医学.临床生物化学与检验学分册》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107643257B (en) | 2021-01-01 |
| CN105259173B (en) | 2018-01-30 |
| CN105259173A (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Garry et al. | A micro method for serum cholinesterase | |
| CN111876465B (en) | High-stability ALP (alpha-amyloid peptide) determination kit and preparation method and application thereof | |
| Thode et al. | Evaluation of a new semiautomatic electrode system for simultaneous measurement of ionized calcium and pH | |
| US2186902A (en) | Urine acetone test | |
| CN105259173B (en) | A kind of composite reagent and its application and the kit containing the composite reagent | |
| US4448889A (en) | Fluid analysis | |
| Billing et al. | The value of needle biopsy in the chemical estimation of liver lipids in man | |
| Stewart | Evaluation of a reagent-strip method for glucose in whole blood, as compared with a hexokinase method. | |
| CN101762577B (en) | Two-step enzyme testing method of triglycercide in blood serum | |
| Whitehead | Advances in quality control | |
| CN105838775A (en) | Kit for detecting leucyl aminopeptidase and preparation method of kit | |
| Raman | Determination of lonized calcium in serum with a calcium electrode | |
| CN105842437A (en) | Kit for detecting D-3-hydroxybutyric acid and preparation method of kit | |
| EA005275B1 (en) | Method for the prediction of preeclampsia and other diseases | |
| EP1754062A1 (en) | Assay system with in situ formation of diazo reagent | |
| US4454230A (en) | Assay method and reagent composition for the determination of magnesium | |
| Han et al. | Application of new reference procedure for ALP measurement in the clinical laboratory | |
| Fesus et al. | Automated determination of urinary Na+, K+, chloride, inorganic phosphate, urea, and creatinine without sample dilution, with the" RA-XT". | |
| KR100255522B1 (en) | Method of assaying metal preseng in biological specimen and reagent therefor | |
| Gitlitz et al. | Interferences with the starch-iodine assay for serum amylase activity, and effects of hyperlipemia. | |
| JP4141137B2 (en) | Measuring method and measuring reagent for small intestine type alkaline phosphatase | |
| Han et al. | Sigma Metrics used to Evaluate the Performance of Internal Quality Control in a Clinical Biochemistry Laboratory. | |
| WO2017006409A1 (en) | Method for transmitting accuracy to measurement method using diluted plasma as test sample | |
| CN106093017A (en) | A kind of test kit measuring Ischemia modified albumin IMA and preparation method thereof | |
| JP2004258025A (en) | Reagent and method for measuring total protein in sample |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |